CL2021003244A1 - Tratamientos de angioedema hereditario - Google Patents

Tratamientos de angioedema hereditario

Info

Publication number
CL2021003244A1
CL2021003244A1 CL2021003244A CL2021003244A CL2021003244A1 CL 2021003244 A1 CL2021003244 A1 CL 2021003244A1 CL 2021003244 A CL2021003244 A CL 2021003244A CL 2021003244 A CL2021003244 A CL 2021003244A CL 2021003244 A1 CL2021003244 A1 CL 2021003244A1
Authority
CL
Chile
Prior art keywords
treatments
hereditary angioedema
hae
demand
present
Prior art date
Application number
CL2021003244A
Other languages
English (en)
Inventor
Edward Paul Feener
Sally Louise Marsh
Andreas Maetzel
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of CL2021003244A1 publication Critical patent/CL2021003244A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

La presente invención se refiere a tratamientos de an-gioedema hereditario (HAE). En particular, la presente invención proporciona tratamientos a solicitud de an-gioedema hereditario (HAE) mediante la administración oral de un inhibidor de calicreína del plasma a un pa-ciente que lo necesita a solicitud. Se proporciona tam-bién tratamientos regulares (o continuos) de HAE.
CL2021003244A 2019-06-14 2021-12-06 Tratamientos de angioedema hereditario CL2021003244A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962861725P 2019-06-14 2019-06-14
GBGB1910116.1A GB201910116D0 (en) 2019-07-15 2019-07-15 Treatments of hereditary angioedema

Publications (1)

Publication Number Publication Date
CL2021003244A1 true CL2021003244A1 (es) 2022-09-30

Family

ID=67700145

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003244A CL2021003244A1 (es) 2019-06-14 2021-12-06 Tratamientos de angioedema hereditario
CL2023000639A CL2023000639A1 (es) 2019-06-14 2023-03-06 Tratamientos de angioedema hereditario

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023000639A CL2023000639A1 (es) 2019-06-14 2023-03-06 Tratamientos de angioedema hereditario

Country Status (30)

Country Link
US (1) US20220218680A1 (es)
EP (2) EP4282474A3 (es)
JP (2) JP7356518B2 (es)
KR (1) KR20220024220A (es)
CN (1) CN114126612A (es)
AR (1) AR119158A1 (es)
AU (1) AU2020293614B2 (es)
BR (1) BR112021024664A2 (es)
CA (1) CA3142218A1 (es)
CL (2) CL2021003244A1 (es)
DK (1) DK3982960T3 (es)
EA (1) EA202193019A1 (es)
ES (1) ES2956471T3 (es)
FI (1) FI3982960T3 (es)
GB (1) GB201910116D0 (es)
HR (1) HRP20230696T1 (es)
HU (1) HUE063163T2 (es)
IL (1) IL288615A (es)
LT (1) LT3982960T (es)
MA (1) MA56187B1 (es)
MD (1) MD3982960T2 (es)
MX (1) MX2021014557A (es)
PL (1) PL3982960T3 (es)
PT (1) PT3982960T (es)
RS (1) RS64412B1 (es)
SG (1) SG11202113304YA (es)
SI (1) SI3982960T1 (es)
TW (1) TW202112370A (es)
WO (1) WO2020249977A1 (es)
ZA (1) ZA202110685B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2022084693A1 (en) * 2020-10-23 2022-04-28 Kalvista Pharmaceuticals Limited Treatments of angioedema
EP4291186A1 (en) 2021-02-09 2023-12-20 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema
WO2023209381A1 (en) 2022-04-27 2023-11-02 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (zh) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PL2999697T3 (pl) 2013-05-23 2017-09-29 Kalvista Pharmaceuticals Limited Pochodne heterocykliczne
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
LT3982960T (lt) 2023-08-25
SI3982960T1 (sl) 2023-10-30
AU2020293614A1 (en) 2022-01-27
RS64412B1 (sr) 2023-09-29
EP4282474A3 (en) 2024-02-14
CN114126612A (zh) 2022-03-01
JP2023166406A (ja) 2023-11-21
MD3982960T2 (ro) 2023-12-31
FI3982960T3 (fi) 2023-08-29
MA56187B1 (fr) 2023-09-27
US20220218680A1 (en) 2022-07-14
EP3982960B1 (en) 2023-06-28
SG11202113304YA (en) 2021-12-30
DK3982960T3 (da) 2023-08-21
WO2020249977A1 (en) 2020-12-17
IL288615A (en) 2022-02-01
EP3982960A1 (en) 2022-04-20
MA56187A (fr) 2022-04-20
PL3982960T3 (pl) 2024-01-15
HUE063163T2 (hu) 2023-12-28
GB201910116D0 (en) 2019-08-28
JP2022536287A (ja) 2022-08-15
TW202112370A (zh) 2021-04-01
AR119158A1 (es) 2021-12-01
BR112021024664A2 (pt) 2022-05-31
MX2021014557A (es) 2022-01-11
CL2023000639A1 (es) 2023-10-30
PT3982960T (pt) 2023-09-26
ZA202110685B (en) 2024-06-26
EA202193019A1 (ru) 2022-03-24
CA3142218A1 (en) 2020-12-17
EP4282474A2 (en) 2023-11-29
JP7356518B2 (ja) 2023-10-04
ES2956471T3 (es) 2023-12-21
HRP20230696T1 (hr) 2023-10-13
KR20220024220A (ko) 2022-03-03
AU2020293614B2 (en) 2024-08-15

Similar Documents

Publication Publication Date Title
CL2021003244A1 (es) Tratamientos de angioedema hereditario
CL2023000699A1 (es) Tratamientos de angioedema
CR20220070A (es) Inhibidores de parp1
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
NI200900106A (es) Inhibidores de la actividad de la akt.
BR112014008807A2 (pt) compostos de tetra-hidroisoquinolina substituídos como inibidores do fator xia
BR112014028041A2 (pt) tratamento de obesidade hipotalâmica com inibidores de metap2
BR112018011622A2 (pt) método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
BR112014002141A2 (pt) crizotinib para uso no tratamento de câncer
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
BR112018070819A2 (pt) peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo
CL2022000214A1 (es) Inhibidores de enzimas
BR112022012283A2 (pt) Combinações
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
PA8655401A1 (es) Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10
UY35165A (es) Método profiláctico o terapéutico para el síndrome de sjogren
CO2017012986A2 (es) Composición de péptidos multiples que comprende fragmentos ia-2 y pi
MX2021009663A (es) Tratamiento del sindrome de pitt-hopkins.
AR128636A1 (es) Inhibidor de recaptación triple para el tratamiento de la depresión atípica
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
BR112022001138A2 (pt) Métodos de tratamento de esclerose múltipla
BR112022013566A2 (pt) Compostos para distúrbios crônicos